Baricitinib
Overview
Baricitinib is a Janus kinase (JAK) inhibitor used to treat rheumatoid arthritis. It is also under investigation for other autoimmune and inflammatory conditions.
API suppliers (6)
Suppliers of Baricitinib evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 3 of 6 suppliers.
3 of 6 hold a GMP certificate on record in the EU or UK registers
- MSN Laboratories Private LimitedIndia1 active DMF GMP on record
- CHUNGHWA CHEMICAL SYNTHESIS AND BIOTECH CO LTD1 active DMF GMP on record
- APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
- Wisdom Pharmaceutical Co., LtdChina1 active DMF
- NANJING LIBRAVO PHARMACEUTICAL CO LTD1 active DMF
- ZAKLADY FARMACEUTYCZNE POLPHARMA SA1 active DMF
Patent & exclusivity (US)
Per the FDA Orange Book (6 approved US products), the latest listed US patent on Baricitinib expires 30 Nov 2032. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Baricitinib? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.